Preventing Cardiotoxicity in Cancer Survivors
Many highly effective cancer treatments can damage the heart. BIDMC's Cardio-Oncology research program is working to understand the roots of cardiotoxicity with the goal of developing cardioprotective therapies for a rapidly growing population of cancer survivors.
Aarti H. Asnani, MD, is an attending cardiologist in the CVI's Cardio-Oncology Program and a basic and translational researcher in this field. The main focus of Dr. Asnani’s lab is to identify new mechanisms of cardiovascular toxicity associated with commonly used cancer treatments. Zebrafish and mouse models of cardiotoxicity are used to define candidate pathways involved in the pathogenesis of cardiotoxicity, with the goal of developing new cardioprotective therapies that target these mechanisms in patients.
Ongoing projects in the Asnani lab focus on the following areas:
- Cytochrome P450 family 1 enzymes in doxorubicin heart toxicity
- Redox biology and characterization of mitochondrial mass and function in doxorubicin heart toxicity
Discovery of new metabolite and protein markers of toxicity in patients treated with cardiotoxic chemotherapy
Development of new animal models to study the tissue-specific effects of cancer treatments
Cardiac Toxicity of Cancer Chemotherapy
Asnani Lab Members
Anita Vohra, BS, Research assistant
Cole Turissini, Summer student
Shu Yang, MD, Resident in Internal Medicine, BIDMC
Anuradha Godishala, MD, Fellow in Cardiovascular Medicine, BIDMC